Document resource
Introduction Reducing wakefulness throughout the night without residual effects the next morning are essential characteristics for drugs for chronic insomnia disorder. Here we examine the effect of daridorexant on wakefulness throughout the night and next-morning sleepiness.Methods Data from 930 patients with insomnia disorder randomized to daridorexant 50 mg, 25 mg or placebo for 3 months were analyzed. Polysomnography-determined WASO by quarter of the night (Q1 to Q4) at Month (M)1 and M3 of treatment, and morning sleepiness upon awakening by a visual analogue scale (VAS).were assessed.Results Decreases in WASO in Q2-4 of the night were numerically larger in both daridorexant dose groups versus placebo.. At M1 and M3, both daridorexant 50mg and 25mg reduced WASO across Q2-4vs placebo.VAS morning sleepiness scores increased (i.e. improved) from Day 1 of treatment in all groups and continued to improve as treatment continued, with larger effects seen with daridorexant 50 mg and 25 mg than placebo.Conclusion In patients with insomniadisorder, daridorexant reduces wakefulness throughout the entire night while decreasing morning sleepiness upon awakening.Funding Idorsia Pharmaceuticals LtdOriginally presented at Sleep Europe 2024, Seville, Spain, P1213james.khoo@idorsia.com